Antiplatelet treatment

PreclinicalSmall molecule

UUniversity of Calgary

Antiplatelet treatment is one of 4 small molecule programs targeting Antiplatelet. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AntiplateletUnknown status

AntiplateletPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Antiplatelet

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

15 2

Colcrys

Jazz Pharmaceuticals

Approved

2 3

Cysteine Hydrochloride

Novartis

Phase 3

1 4

Antiplatelet treatment

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiplatelet1 trial

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

Unknown status·HHamilton Health Sciences Corporation·N/A·NCT03005704·10 enrolled

Ischemic stroke1 trial

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

Completed·UUniversity of Calgary·Phase 3·NCT02398656·1,274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Antiplatelet treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiplatelet treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiplatelet treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Calgary

Antiplatelet treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiplatelet1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News